Skip to content

Fable Ther­a­peu­tics

Using state-of-the-art machine learning models to create custom-build protein drugs

First Investment: 2024

Biologic drugs such as semaglutide, a peptide now helping millions of people to lose weight and control diabetes, have tradi­tion­ally been developed by mimicking existing biological molecules or isolating and laboriously tweaking the genes that encode them. But now it’s possible to use advanced forms of AI to design new proteins from scratch. Fable is applying diffusion models and other forms of machine learning to public and private datasets housing billions of protein and sequences and structures, with the goal of crafting novel, precision-engineered peptides and antibodies that could far outperform existing drugs.

Explore Companies